Iovance Biotherapeutics (NASDAQ: IOVA) didn't quite end the stock trading week on a high note. The company's shares were dinged by almost 6% that day, due largely to an analyst's recommendation ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Bolt Biotherapeutics Inc. (BOLT) on Monday reported a loss of $11 million in its first quarter. On a per-share basis, the Redwood City ...

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the ...

Analysts' ratings for Iovance Biotherapeutics IOVA over the last quarter vary from bullish to bearish, as provided by 9 analysts. The table below provides a concise overview of recent ratings by ...

SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Thursday reported a loss of $116.2 million in its first quarter. On a per-share basis, the San Carlos ...

Iovance Biotherapeutics (NASDAQ:IOVA) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.

Arcutis Biotherapeutics ( (ARQT)) has provided an announcement. On April 10, 2025, Arcutis Biotherapeutics announced the appointment of Latha Vairavan as the new Chief Financial Officer ...

Arcutis Biotherapeutics has a 12 month low of $6.99 and a 12 month high of $17.75. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -8.23 and a beta of 1.67.

Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The firm had revenue of $73.69 million during the quarter, compared to analysts ...